Press Releases

Endonovo Therapeutics Hires David Clark as Vice President of Sales

Download PDF

Los Angeles, May 03, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced veteran sales leader David Clark joined as Endonovo’s Vice President of Sales. In his new position, Mr. Clark will lead the U.S. Sales Team, distributors and strategic partners through the next phase of growth. He'll be working with distributors, outside sales representatives and building an internal sales force to expand coverage and build high-value programs for customer support.

Mr. Clark has 25 years of surgical device commercial experience with leading companies, including Medtronic and Baxter. Mr. Clark was most recently Executive Vice President of Sales for Biom’up, including the launch of surgical hemostat HEMOBLAST Bellows™. He built and led the U.S. Biom’up Sales Team, consisting of 200 plus in-direct sales representatives and direct commercial leaders. David holds a B.A. in Economics from Rutgers University.

David Clark proclaimed, “I’m thrilled to join the Endonovo Therapeutics Team as there exists tremendous passion and excitement within the organization regarding our SofPulse® technology and being presented such a unique opportunity to so greatly impact patients’ lives”

Alan Collier, Endonovo’s Chief Executive Officer, stated, “Endonovo continues to transform its business at a rapid pace. Over the past year the company has focused on clinical studies, building an expert management team and developing strategic partnerships. The focus now shifts to revenue growth and are fortunate to announce key hires leading our national rollout. The incredible talent we’ve assembled continues to make an impact and adding senior leadership only further underscores our commitment to serve.

“I am excited David has decided to join us as his leadership style and personality perfectly complement our fast-paced, rapidly growing organization. Our entry into hospitals and medical care facilities is just the beginning of what we believe will be leading the charge against the opioid epidemic,” concluded Mr. Collier.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki


Source: Endonovo Therapeutics, Inc.